Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
March 11 2019 - 7:30AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will participate in two fireside chat presentations at the
following investor conferences:
March 18, 12:30 p.m. PT; 31st Annual Roth Conference, Dana
Point, CA
March 20, 9:45 a.m. ET; Oppenheimer’s 29th Annual Healthcare
Conference, New York City.
A live webcast of each presentation will be accessible by
visiting the “Events and Presentations” section on the “Investors”
page of Enanta’s website at www.enanta.com. A replay of the
webcasts will be available following the presentation and will be
archived for approximately 30 days.
About EnantaEnanta Pharmaceuticals is using its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery and development of small molecule drugs
for the treatment of viral infections and liver diseases. Enanta’s
research and development efforts are currently focused on the
following disease targets: respiratory syncytial virus (RSV),
non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), and hepatitis B virus (HBV).
Enanta’s research and development activities are currently
funded by royalties from HCV products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is now sold by AbbVie in numerous countries
as part of its newest treatment for chronic hepatitis C virus (HCV)
infection. This leading HCV regimen is sold under the tradenames
MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir).
Please visit www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190311005008/en/
Carol Miceli617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024